Bicara Therapeutics (NASDAQ:BCAX) CEO Claire Mazumdar Sells 6,905 Shares

Bicara Therapeutics Inc. (NASDAQ:BCAX) CEO Claire Mazumdar sold 6,905 shares of the stock in a transaction on Thursday, March 19th. The shares were sold at an average price of $18.78, for a total value of $129,675.90. Following the transaction, the chief executive officer directly owned 339,392 shares of the company’s stock, valued at approximately $6,373,781.76. This trade represents a 1.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Claire Mazumdar also recently made the following trade(s):

• On Wednesday, March 18th, Claire Mazumdar sold 6,499 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.84, for a total value of $122,441.16.
• On Friday, March 20th, Claire Mazumdar sold 1,596 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.95, for a total value of $30,244.20.
• On Monday, March 9th, Claire Mazumdar sold 36,766 shares of Bicara Therapeutics stock. The stock was sold at an average price of $19.17, for a total value of $704,804.22.
• On Friday, March 6th, Claire Mazumdar sold 3,817 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.75, for a total value of $71,568.75.
• On Wednesday, March 4th, Claire Mazumdar sold 2,631 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.73, for a total value of $49,278.63.
• On Thursday, March 5th, Claire Mazumdar sold 1,786 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.74, for a total value of $33,469.64.

Bicara Therapeutics Stock Performance

NASDAQ BCAX traded down $0.38 during trading on Friday, hitting $18.41. 1,190,900 shares of the company’s stock traded hands, compared to its average volume of 515,465. The stock has a market capitalization of $1.01 billion, a price-to-earnings ratio of -8.22 and a beta of -0.78. Bicara Therapeutics Inc. has a 12-month low of $7.80 and a 12-month high of $20.25. The business has a 50 day moving average of $16.98 and a 200-day moving average of $16.27.

Analyst Ratings Changes

Several research firms have issued reports on BCAX. Citigroup started coverage on Bicara Therapeutics in a research report on Thursday, January 29th. They set an “outperform” rating on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Friday, January 9th. BTIG Research reissued a “buy” rating on shares of Bicara Therapeutics in a report on Thursday, January 15th. UBS Group reaffirmed a “buy” rating on shares of Bicara Therapeutics in a report on Wednesday, January 14th. Finally, Mizuho upgraded Bicara Therapeutics to a “hold” rating in a research report on Thursday, December 18th. Six analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Bicara Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $30.25.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in BCAX. Legal & General Group Plc boosted its stake in Bicara Therapeutics by 64.1% during the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after buying an additional 1,233 shares during the period. Ameritas Investment Partners Inc. increased its stake in Bicara Therapeutics by 73.0% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock worth $32,000 after acquiring an additional 1,474 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in Bicara Therapeutics by 419.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after acquiring an additional 3,866 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Bicara Therapeutics in the 4th quarter valued at about $45,000. Finally, Larson Financial Group LLC raised its holdings in shares of Bicara Therapeutics by 1,015.5% in the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock valued at $62,000 after acquiring an additional 3,595 shares in the last quarter.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.